Entrada Therapeutics (TRDA) Return on Invested Capital (2023 - 2026)

Entrada Therapeutics has reported Return on Invested Capital for 4 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Invested Capital fell 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (down 1.0% YoY), and the FY2025 full-year result was 0.0%, down 1.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.01%, down from 0.0% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.0% in Q2 2024, with the low at 0.01% in Q1 2026.
• Average Return on Invested Capital over 4 years is 0.0%, with a median of 0.0% recorded in 2023.
• Year-over-year, Return on Invested Capital climbed 1 bps in 2024 and declined 1 bps in 2025.
• Tracing TRDA's Return on Invested Capital over 4 years: stood at 0.0% in 2023, then surged by 1445 bps to 0.0% in 2024, then slumped by 551 bps to 0.0% in 2025, then decreased by 27 bps to 0.01% in 2026.
• The last three Return on Invested Capital figures came in at 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.

Peer Comparison